How are energy investors positioned?
Aspira Women’s Health Inc. (NASDAQ:AWH), a company specializing in diagnostic substances, has announced significant changes in its executive team. Dr. Sandra Milligan, the President of Aspira, will resign for personal reasons effective February 21, 2025. Following Dr. Milligan’s departure, Jamie Sullivan, Chief of Staff and ARPA-H Program Director, along with Todd Pappas, Vice President of Research & Development and Laboratory Operations, will assume her responsibilities.
In addition, on February 6, 2025, the Board of Directors appointed Ellen Beausang as a new member. Beausang brings over 25 years of experience in the pharmaceutical and diagnostic industry, having held significant roles at Pfizer (NYSE:PFE), Thermo Fisher (NYSE:TMO) Diagnostics, and Quest Diagnostics (NYSE:DGX). Her expertise in go-to-market strategies and product development is expected to be valuable to Aspira, which reported revenue of $8.96 million in the last twelve months with a gross profit margin of 58.12%. Beausang, who has a B.S. in Psychology/Sociology from SUNY Brockport and an M.S. in Clinical Psychology from Seton Hall University, has been serving as President-Chief Commercial Officer at BioReference Health since June 2022.
The company clarified that there are no familial relations or related-person transactions involving Beausang that would require disclosure under SEC regulations. These executive changes come at a time when Aspira Women’s Health continues to focus on its mission to innovate in the field of women’s health diagnostics.
This news is based on the latest 8-K filing with the Securities and Exchange Commission and reflects the company’s commitment to transparency in its corporate governance. Aspira Women’s Health, formerly known as Vermillion , Inc., Ciphergen Biosystems Inc, and Abiotic Systems, is headquartered in Austin, Texas, and operates under Delaware incorporation laws. The updates to the executive team are part of the company’s ongoing efforts to adapt and grow in the competitive healthcare sector.
In other recent news, Aspira Women’s Health has experienced significant changes in its executive leadership and faced regulatory challenges. The company appointed Michael Buhle as CEO and James Crawford as VP of Finance, with Dr. Sandra Milligan continuing as President. This came after the resignation of Interim CFO John Kallassy, with Milligan assuming his duties. Furthermore, Aspira is contending with potential delisting from the Nasdaq Capital Market due to not meeting the minimum Market Value of Listed Securities requirement.
Despite these challenges, Aspira reported a 2% increase in OvaSuite revenue to $2.3 million for the third quarter of 2024, with test volume growing by 4%. The company also received a $10 million federal award from ARPA-H to develop ENDOinform, a test for endometriosis. Aspira is focused on expanding its ovarian cancer portfolio and enhancing commercial capabilities.
These recent developments underscore the dynamic nature of Aspira Women’s Health’s operations and its commitment to advancing diagnostic options for women’s health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.